Delayed First Injection Of The Once-a-month Injectable Contraceptive Containing 25 Mg Of Medroxyprogesterone Acetate And 5 Mg Of E2-cypionate: Effects On Ovarian Function

dc.creatorPetta C.A.
dc.creatorHays M.
dc.creatorBrache V.
dc.creatorMassai R.
dc.creatorHua Y.
dc.creatorAlvarez-Sanchez F.
dc.creatorCroxatto H.
dc.creatorD'Arcangues C.
dc.creatorCook L.A.
dc.creatorBahamondes L.
dc.date2001
dc.date2015-06-26T14:44:00Z
dc.date2015-11-26T14:17:25Z
dc.date2015-06-26T14:44:00Z
dc.date2015-11-26T14:17:25Z
dc.date.accessioned2018-03-28T21:18:30Z
dc.date.available2018-03-28T21:18:30Z
dc.identifier
dc.identifierFertility And Sterility. , v. 75, n. 4, p. 744 - 748, 2001.
dc.identifier150282
dc.identifier10.1016/S0015-0282(01)01672-7
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-0035075506&partnerID=40&md5=80ee60544a499b8292818423cd76daf9
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/95243
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/95243
dc.identifier2-s2.0-0035075506
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1243333
dc.descriptionObjective: To assess whether women who were administered the first injection of DMPA+E2C on day 7 of their menstrual cycle (delayed injection) exhibit the same degree of ovarian suppression as women who receive it on day 5 of their menstrual cycle. Design: Multicenter, randomized controlled trial.Setting: Reproductive health clinics. Patient(s): Women aged between 18 and 38 years (inclusive) willing to use DMPA+E2C as their method of contraception. Intervention(s): Participants received a DMPA+E2C injection on day 5 (control group, n = 41) or day 7 (delayed-injection group, n = 117) of their menstrual cycle. Main Outcome Measure(s): Ovarian activity and follicular development determined by serial serum progesterone levels and vaginal ultrasound. Result(s): Participants who received DMPA+E2C on day 5 of their menstrual cycle (control group) exhibited no more than limited follicular growth (no follicle >16 mm). Of those women who received DMPA+E2C on day 7 of their menstrual cycle (delayed-injection group), 21 (18%) showed some follicular growth, of whom 4 (3%) ovulated. Conclusion(s): The first injection of DMPA+E2C given on day 7 of a menstrual cycle does not provide the same inhibition of ovarian activity as that observed when it is administered on day 5 of the menstrual cycle. Copyright © 2001 American Society for Reproductive Medicine.
dc.description75
dc.description4
dc.description744
dc.description748
dc.descriptionHall PE, Task Force on Research on Introduction and Transfer of Technologies for Fertility Regulation, Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland. The introduction of Cyclofem into national family planning programmes: experience from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia. Contraception 1994;49:489-507Hall, P., Bahamondes, L., Diaz, J., Petta, C., Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia, and Peru (1997) Contraception, 56, pp. 353-359
dc.descriptionTechnical Guidance/Competence Working Group (TC/CWG). Recommendations for updating selected practices in contraceptive use. World Health Organization/USAID, 1997Ritchie, W.G., Ultrasound in the evaluation of normal and induced ovulation (1985) Fertil Steril, 43, pp. 167-181
dc.descriptionBrache, V., Alvarez, F., Faundes, A., Cochon, L., Thevenin, F., Effect of preovulatory insertion of Norplant implants over luteinizing hormone secretion and follicular development (1996) Fertil Steril, 65, pp. 1110-1114
dc.descriptionGarza-Flores, J., Rodriguez, V., Perez-Palacios, G., Virutamasen, P., Tang-Keow, P., Konsayreepong, R., A multicentered pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives. I. Different doses of HRP112 and of DepoProvera. World Health Organization Task Force on Long-acting Systemic Agents for Fertility Regulation (1987) Contraception, 36, pp. 441-457
dc.descriptionPetta, C.A., Faundes, A., Dunson, T.R., Ramos, M., DeLucio, M., Faundes, D., Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function (1998) Fertil Steril, 70, pp. 817-820
dc.descriptionSperoff, L., Glass, R.H., Kase, N.G., (1994), p. 191. , Clinical gynecologic endocrinology and infertility, Baltimore, MD: Williams and WilkinsBrache, V., Blumenthal, P.D., Alvarez, F., Dunson, T.R., Cochon, L., Faundes, A., Timing of onset of contraceptive effectiveness in Norplant implant users. II. Effect on the ovarian function in the first cycle of use (1999) Contraception, 59, pp. 245-251
dc.descriptionJordan, J., Craig, K., Clifton, D.K., Soules, M.R., Luteal phase defect
dc.descriptionthe sensitivity and specificity of diagnostic methods in common clinical use (1994) Fertil Steril, 62, pp. 54-62
dc.descriptionGarza-Flores, J., Sang, G.W., Hall, P.E., Population and delivery systems
dc.descriptionvariability in pharmacokinetics of long-acting injectable contraceptives (1994), pp. 69-83. , Snow R., Hall P.E. (Eds.), Steroid contraceptives and women's response. Regional variability and side-effects and pharmacokinetics, New York: Plenum Press
dc.languageen
dc.publisher
dc.relationFertility and Sterility
dc.rightsfechado
dc.sourceScopus
dc.titleDelayed First Injection Of The Once-a-month Injectable Contraceptive Containing 25 Mg Of Medroxyprogesterone Acetate And 5 Mg Of E2-cypionate: Effects On Ovarian Function
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución